1910 GeneticsMake undruggable targets a thing of the past

1910 Genetics accelerates drug development with AI-powered platforms, ELVIS™ and ROSALYND™, designing both small molecule and protein therapeutics. Discover innovative medicines for neuroscience, infectious diseases, immunology, and oncology.

AI-Powered Drug Discovery

Small Molecule & Protein Therapeutics

End-to-End Drug Discovery Platform

1910 Genetics Alternatives

Sequence Bio

Discovering the true signals of disease to power life-changing drugs.

Verge Genomics

We use human data and AI to develop better drugs faster.

Nabla Bio

We use AI to design antibodies for intractable diseases

Junction Bioscience

AI Hypothesis Engine for Molecular Discovery

Entvin

Arpeggio Bio

Arpeggio Bio develops drugs targeting transcription factors using AI…

Medium Biosciences

AI to design any biomolecule for any function

WhiteLab Genomics

Unleashing the potential of DNA and RNA based therapies using AI

Output Biosciences

Teaching Generative AI the Language of Biology

GEn1E Lifesciences

AI platform accelerating therapies for rare & inflammatory diseases.

Biocartesian

Converting biology into digital molecular maps

Serna Bio

Mapping the druggable transcriptome

Talus Bio

Discovering drugs that target the DNA regulome

Pando Bioscience

Gen-AI Designed Enzymes for Pharmaceutical Innovation

Atomwise

Artificial intelligence for drug discovery.

1910 Genetics

1910 Genetics is a leading AI-powered drug discovery company focused on developing novel therapeutics for neurological, autoimmune, and cancer diseases. Their AI platform integrates computational data and wet lab proxy biological data to enable them to identify and produce new drug molecules with greater efficiency and accuracy.

Product Highlights

Feature 1: Multimodal AI platform to support drug discovery.
Feature 2: Integrates computational data and wet lab proxy biological data.
Feature 3: Develops novel drug candidates for neurological, autoimmune, and cancer diseases.

Use Cases

Use case 1: Developing novel therapeutics for neurological diseases.
Use case 2: Developing novel therapeutics for autoimmune diseases.
Use case 3: Developing novel therapeutics for cancer.

Target Audience

Leading pharmaceutical and technology companies, as well as researchers and academics interested in drug discovery.